Ligand Pharmaceuticals Inc represents values of innovation, collaboration, and integrity in the pharmaceutical industry. The company is committed to discovering and developing breakthrough medicines that address unmet medical needs. With a strong focus on research and development, Ligand strives to develop novel therapies that improve patient outcomes. The company's corporate philosophy centers around teamwork and partnerships, as it collaborates with leading pharmaceutical companies to bring innovative therapies to market. Through its cutting-edge technology platforms and strategic acquisitions, Ligand Pharmaceuticals Inc continues to make significant contributions to the advancement of modern medicine.

Ligand Pharmaceuticals Inc is primarily present in the United States and holds a strong presence in other regions such as Europe and Asia. As a leading biopharmaceutical company, Ligand has strategically established its global footprint to capitalize on market opportunities and expand its reach. With a commitment to innovation and collaboration, Ligand aims to enhance patient care and deliver transformative therapies worldwide.

Ligand Pharmaceuticals Inc has achieved several significant milestones throughout its history. Some notable accomplishments include the successful development and commercialization of various novel therapeutics across multiple therapeutic areas. The company has also formed strategic collaborations with renowned pharmaceutical companies, which have helped expand its product portfolio and global reach. Ligand Pharmaceuticals Inc has received multiple regulatory approvals for its innovative drugs, demonstrating its commitment to delivering high-quality and effective treatments. The company's successful track record in research and development, coupled with its strong partnerships, has positioned Ligand Pharmaceuticals Inc as a leading player in the pharmaceutical industry.

Ligand Pharmaceuticals Inc is a renowned biopharmaceutical company that specializes in developing and acquiring technologies for the discovery and development of innovative drugs. Established in 1987, the company has a rich history of pioneering advancements in drug discovery. Ligand Pharmaceuticals Inc operates on a unique business model, utilizing its comprehensive proprietary libraries of drug candidates, which are made available to partners for licensing. This approach has facilitated numerous successful partnerships and collaborations, leading to the approval and commercialization of multiple life-changing therapies. Ligand Pharmaceuticals Inc continues to demonstrate its commitment to advancing medicine through strategic collaborations, research, and development efforts.

The main competitors of Ligand Pharmaceuticals Inc in the market are Amgen Inc., Eli Lilly and Company, and Pfizer Inc.

Ligand Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

Ligand Pharmaceuticals Inc's business model focuses on developing and licensing innovative therapies and technologies for the biopharmaceutical industry. As a leading drug discovery and development company, Ligand partners with pharmaceutical and biotechnology companies to provide access to its broad portfolio of intellectual property, expertise, and research tools. By leveraging their unique Captisol® technology, Ligand is able to enhance the solubility and efficacy of active pharmaceutical ingredients, enabling the development of novel therapies. This business model allows Ligand to generate significant revenue through strategic collaborations and royalty-bearing partnerships while minimizing the risk associated with drug development.

Το Ligand Pharmaceuticals P/E είναι 19,02.

Το KUV της εταιρείας Ligand Pharmaceuticals είναι 11,98.

Το AlleAktien Qualitätsscore για το Ligand Pharmaceuticals είναι 3/10.

Ο κύκλος εργασιών του αναμενόμενη Ligand Pharmaceuticals είναι 156,78 Εκ. USD.

Το αναμενόμενη Ligand Pharmaceuticals κέρδος είναι 98,80 Εκ. USD.

Ligand Pharmaceuticals Inc. is a biopharmaceutical company focused on researching and developing novel medications. The company's business model is based on identifying, developing, and marketing unique therapeutics specialized in various disease areas. The company operates in three main business segments: Captisol Platform Technology, OmniAb Antibody Research, and Partnered Programs. The Captisol Platform Technology is a patented technology for the production of drugs that helps improve drug solubility and bioavailability. This technology is also used for the production of generics to make them patent-protected and more economically viable. The second segment is OmniAb Antibody Research. This involves an innovative strategy for developing antibody-based therapeutics that can be used for the treatment of cancer, inflammatory, and infectious diseases. This research involves the identification of antibodies specific to target molecules, thus providing effective therapeutics. The third segment, Partnered Programs, focuses on collaborations with other companies. It aims to build a comprehensive network of biotechnology and pharmaceutical companies to jointly develop and market new therapeutics. Ligand offers its partners access to its patented technologies and expertise in the development of new therapeutics. One of Ligand's key products is the orally administered hormone therapy Lasofoxifene, used for the treatment of osteoporosis in postmenopausal women. Additionally, Ligand also holds the license for the distribution of Promacta, a medication developed in collaboration with GlaxoSmithKline for the treatment of thrombocytopenia. Overall, Ligand Pharmaceuticals Inc. highly values partnerships to enhance its innovation and success in the industry. The company relies on its ability to develop innovative technologies and build connections with customers and partners to expand its business. With its patented technologies and expertise in drug research and development, Ligand strives to improve the lives of patients and enhance healthcare overall.

Η Ligand Pharmaceuticals καταβάλλει μια διανομή της τάξεως των 0 USD διαμοιρασμένη σε δόσεις ετησίως.

Το μέρισμα δεν μπορεί να υπολογιστεί για το Ligand Pharmaceuticals αυτή τη στιγμή ή η εταιρεία δεν διανέμει μέρισμα.

Ο αριθμός ISIN της Ligand Pharmaceuticals είναι US53220K5048.

Το WKN της Ligand Pharmaceuticals είναι A1C9RN.

Ο τίκερ της Ligand Pharmaceuticals είναι LGND.

Κατά τους τελευταίους 12 μήνες η Ligand Pharmaceuticals κατέβαλε μια μέρισμα ύψους 15,00 USD . Αυτό αντιστοιχεί σε απόδοση μερίσματος περίπου 14,18 %. Για τους επόμενους 12 μήνες, η Ligand Pharmaceuticals προβλέπεται να πληρώσει μέρισμα 0 USD.

Η απόδοση μερίσματος της Ligand Pharmaceuticals ανέρχεται σήμερα στο 14,18 %.

Ligand Pharmaceuticals πληρώνει τέταρτον διανεμητέου μισθό. Αυτή καταβάλλεται τους μήνες .

Η Ligand Pharmaceuticals πλήρωσε κάθε χρόνο μέρισμα μέσα στα τελευταία 0 έτη.

Για τους επόμενους 12 μήνες αναμένονται μερίσματα σε ύψος των 0 USD. Αυτό αντιστοιχεί σε απόδοση μερίσματος 0 %.

Το Ligand Pharmaceuticals ανατίθεται στον τομέα 'Υγεία'.

Για να λάβεις το τελευταίο μέρισμα των Ligand Pharmaceuticals από την 19/4/2007 με τιμή 2,5 USD, έπρεπε να έχεις τη μετοχή στο χαρτοφυλάκιο σου πριν από την ημέρα Ex-Tag στις 3/4/2007.

Η τελευταία μερίσματος έγινε στις 19/4/2007.

Το έτος 2023, η Ligand Pharmaceuticals διένειμε 0 USD ως μερίσματα.

Τα μερίσματα του Ligand Pharmaceuticals καταβάλλονται σε USD.